Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2
The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1
“The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which are supported by the highest quality scientific evidence.”
The foundation of Janssen’s scientific understanding in prostate cancer is based on the knowledge acquired through the development of innovative treatment options for mCRPC. Abiraterone acetate is an oral androgen biosynthesis inhibitor that is approved for the treatment of both mCRPC and metastatic hormone-sensitive prostate cancer, in Europe.3,4
“The addition of abiraterone acetate to the Essential Medicines List is a significant milestone for Janssen Oncology, reflecting the tireless efforts in recent years to bring optimal treatment options to patients with mCRPC,” said Biljana Naumovic, Vice President Commercial Strategy Lead Oncology for Europe, Middle East & Africa, Cilag GmbH International. “This direction from the WHO further emphasises that our work is not yet over. It is critical that patients with prostate cancer have access to treatments that their clinicians feel can benefit them and that we continue to support the prostate cancer community in our common goal of making cancer a manageable and potentially one day, a curable condition.”
# ENDS #
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA for our latest news. Janssen-Cilag S.A. and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About abiraterone acetate (ZYTIGA®)
Abiraterone acetate plus prednisone/prednisolone is an approved therapy in mCRPC that inhibits production of androgens (which fuel prostate cancer growth) at all three sources that are important in prostate cancer - the testes, adrenals and the tumour itself.4,5,6
Abiraterone acetate is an oral therapy, taken in combination with prednisone/prednisolone for the treatment of:4
- newly diagnosed high risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
- mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated
- mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen
###
References
1 World Health Organisation. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access. Available at https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access. Last accessed July 2019.
2 World Health Organisation. World Health Organization Model List of Essential Medicines. Available at: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?sequence=1&isAllowed=y. Last accessed July 2019.
3
Bedoya DJ and Mitsiades N (2012). Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 12(1), 1–3.
4 European Medicines Agency. Zytiga Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf. Last accessed July 2019.
5 Hoy, SM. et al. Abiraterone Acetate: A review of its use in patients with metastatic castration-resistant prostate cancer drugs. Drugs 2013; 73:2077-2091.
6 Ritch, CR. Cookson, MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;355:i4405. Doi: 10.1136/bmj.i4405.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190719005230/en/
Contact information
Media Enquiries:
Laura Coughlan
Phone: +353 87 147 9356
Investor Relations:
Christopher DelOrefice
Phone: +1 732 524 2955
Lesley Fishman
Phone: +1 732 524 3922
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Releases 2025 1.0.1 with Enhancements for CAD Translation, Model Simplification, and Mesh Preparation for Manufacturing and Simulation2.5.2025 17:47:00 EEST | Press release
Spatial Corp., the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announces the 2025 1.0.1 release and updates across several product lines, reaffirming its commitment to providing innovative solutions for its customers in domains ranging from CAD to simulation, manufacturing, and beyond. The 2025 1.0.1 release delivers expanded functionality designed to streamline manufacturing and simulation workflows. Key highlights include a new custom feature detection API in ACIS for more efficient model simplification, expanded CAD format support—including STEP AP242 PMI writing—and continued enhancements to hidden-body removal. With this release, Spatial reduces manual tasks, increases fidelity in geometry translation, and strengthens its toolset for automated design-to-manufacture and design-to-simulation pipelines. 3D ACIS Modeler Custom Feature Detection (Beta): Model simplification often requires manua
Decent Cybersecurity Joins the Council of Slovak Exporters to Strengthen European Cybersecurity Exports2.5.2025 16:51:00 EEST | Press release
Decent Cybersecurity, a leading European provider of post-quantum security solutions, announces its membership in the Council of Slovak Exporters (CSE), reinforcing its commitment to expanding advanced cybersecurity exports across global markets. This strategic partnership combines Decent Cybersecurity's expertise in critical infrastructure protection with CSE's established export promotion platform. As a company holding national, EU, and NATO "Secret" level security clearances, Decent Cybersecurity brings specialized knowledge in post-quantum security, blockchain technology, and space traffic management solutions to the Council's network. "Joining the Council of Slovak Exporters represents a significant opportunity to strengthen Slovakia's position in the global cybersecurity market," said Matej Michalko, Founder and CEO of Decent Cybersecurity and a long-term expert on post-quantum cryptography and blockchain. "As cyber threats continue to evolve, our advanced solutions are increasin
Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education2.5.2025 16:29:00 EEST | Press release
Saudi Arabia has taken another step forward in its educational reform journey with the successful conclusion of the International Education Exhibition (EDGEx), held from April 13–16, 2025. Organized by the Ministry of Education, the event convened education leaders, technology developers, and policymakers from around the world under the theme “Beyond Readiness.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250502190798/en/ Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education (Photo: AETOSWire) Over four days, EDGEx welcomed more than 20,000 local and international visitors, including government representatives, senior educators, academics, business leaders, and professionals in the field. The exhibition served as a platform for dialogue, knowledge exchange, and cross-sector collaboration—bringing together institutions, companies, and decision-makers to explore how education and training can evolve in a rapidl
IFF Announces Tender Offers for Certain Outstanding Series of Notes2.5.2025 16:10:00 EEST | Press release
IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread(4) Early Tender Payment (4)(5) 1.230% Senior Notes due 2025 459506AN1 U45950AE9 $1,000 1 $500 million 5.000% UST due 9/30/25 FIT3 + 0 bps $30 1.832% Senior Notes due 2027 459506AP6 U45950AF6 $1,200 2 $300 million 3.750% UST due 4/30/27 FIT1 + 75 bps $30 2.300% Senior Notes due 2030 459506AQ4 U45950AG4 $1,500 3 N/A 3.875% UST due 4/30/30 FIT1 + 110 bps $30 4.450% Senior Notes due 2028 459506AK7 US459506AK78 $400 4 N/A 3.750% UST due 4/15/28 FIT1 + 95 bps $30 Poo
Heidrick & Struggles Appoints a New Managing Partner for Their CEO & Board Practice in Europe and Africa2.5.2025 11:27:00 EEST | Press release
Heidrick & Struggles (Nasdaq: HSII), a premier provider of executive search, global leadership advisory and on-demand talent solutions, has appointed Kati Najipoor-Smith as Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa. Based at the Firm’s office in Frankfurt, Germany, Kati brings decades of global executive search and consulting experience to the Heidrick & Struggles team to support boards and CEOs in navigating complex leadership challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501269229/en/ Kati Najipoor-Smith has been appointed Heidrick & Struggles' Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa Kati began her executive search career at Egon Zehnder in 1999, where she led Global Automotive and later the Global CEO Practice over several years. She advises chairs and CEOs of publicly traded, family-owned, and private-equity-backed companies across sectors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom